Pharmaceutical
Human APIs Powder
- Respiratory Drugs Raw Material
- Antiviral Antibacterial
- Antipyretic Analgesics
- Antihistamine Drugs
- Antineoplastic
- Cosmetic Raw Material
OEM & ODM
Veterinary raw materials
Phone: 86-29-89601602
E-mail: sales21@interlgroup.com
Add: Fengcheng 2nd Road, Weiyang District, Xi'an, Shaanxi, China
Organic intermediates Carbidopa Powder 38821-49-7
Product Overview:
Carbidopa is a strong peripheral dopa decarboxylase inhibitor.
It is not easy to pass through the blood-brain barrier, and when combined with levodopa, it only inhibits the activity of peripheral dopa decarboxylase, reduces the production of dopamine in peripheral tissues, alleviates its peripheral adverse effects, and in turn increases the amount of levodopa entering the centre, improves the concentration of dopamine in the brain, and strengthens the therapeutic efficacy of levodopa, and therefore it is an important adjuvant drug for levodopa.
Carbidopa alone is ineffective, clinically, carbidopa and levodopa are usually made into a compound preparation in the ratio of 1:10 or 1:4.
Organic intermediates Carbidopa Powder 38821-49-7 Attributes
CAS:38821-49-7
MF:C10H16N2O5
MW:244.25
EINECS:642-905-9
Specification: 99% min Carbidopa Powder
Sample: Carbidopa Powder
Packaging:1kg/bag, 25kg/drum
Brand: Henrikang
Appearance: White powder
Storage: Cool Dry Place
Shelf Life: 2 Years
Test Method: HPLC
Organic intermediates Carbidopa Powder 38821-49-7 Details
Carbidopa Powder Usage and Synthesis.
Carbidopa is a strong peripheral dopa decarboxylase inhibitor.
It is not easy to pass through the blood-brain barrier, and when combined with levodopa, it only inhibits the activity of peripheral dopa decarboxylase, reduces the production of dopamine in peripheral tissues, alleviates its peripheral adverse effects, and in turn increases the amount of levodopa entering the centre, improves the concentration of dopamine in the brain, and strengthens the therapeutic efficacy of levodopa, and therefore it is an important adjuvant drug for levodopa.
Carbidopa alone is ineffective, clinically, carbidopa and levodopa are usually made into a compound preparation in the ratio of 1:10 or 1:4.
Uses of Carbidopa.
Carbidopa is a strong peripheral dopa decarboxylase inhibitor.
It is not easy to pass through the blood-brain barrier, and when combined with levodopa, it only inhibits the activity of peripheral dopa decarboxylase, reduces the production of dopamine in peripheral tissues, alleviates its peripheral adverse effects, and in turn increases the amount of levodopa entering the centre, improves the concentration of dopamine in the brain, and strengthens the therapeutic efficacy of levodopa, and therefore it is an important adjuvant drug for levodopa.
Carbidopa alone is ineffective, clinically, carbidopa and levodopa are usually made into a compound preparation in the ratio of 1:10 or 1:4.
Pharmacological Effect of Carbidopa.
Carbidopa is a peripheral decarboxylase inhibitor, not easy to enter the centre, only inhibit the conversion of peripheral levodopa to dopamine, so that the circulating levodopa content increases, and thus the amount of levodopa into the centre increases, levodopa is converted into dopamine by dopamine decarboxylase in the brain to play a pharmacological role in improving the symptoms of tremor paralysis.
Note of Bulk Carbidopa Powder.
1, hypertension, arrhythmia, diabetes mellitus patients with caution.
2、Patients with osteoporosis should resume normal activities slowly to reduce the risk of fracture.
3、Blood test, liver and kidney function and electrocardiogram should be checked during the use of the drug.